Fluocinolone acetonide sustained drug delivery device to treat severe uveitis

被引:174
作者
Jaffe, GJ
Ben-Nun, J
Guo, H
Dunn, JP
Ashton, P
机构
[1] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA
[2] Assaf Hrophe Med Ctr, Tel Aviv, Israel
[3] Control Delivery Syst Inc, Watertown, MA USA
[4] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA
[5] Tufts New England Med Ctr, Boston, MA USA
关键词
D O I
10.1016/S0161-6420(00)00466-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Uveitis is often a chronic disease requiring long-term medical therapy. In this report, we describe a pilot safety and efficacy trial of a novel sustained drug delivery system containing fluocinolone acetonide to treat patients with severe uveitis. Design: Prospective, noncomparative, Interventional case series Participants: Patients with severe uveitis. Methods: Sustained drug delivery devices designed to release fluocinolone acetonide for at least 2.5 years were implanted through the pars plana into the vitreous cavity of seven eyes of five patients. All patients had severe uveitis not well controlled with, or intolerant to, repeated periocular corticosteroid injections, systemic corticosteroids, nonsteroidal immunosuppressive agents, or a combination thereof at the time of device implantation. Before device implantation, patients underwent complete evaluation including history, ophthalmologic examination, fluorescein angiography, visual field testing, and electroretinography. After surgery, patients were reexamined at 1 week, 2 weeks, 4 weeks, and at 1- to 3-month intervals. Visual fields, electroretinograms, and fluorescein angiography were repeated at 3- to 6-month intervals. Main Outcome Measurer Preoperative and postoperative visual acuity, ocular inflammation, anti-inflammatory medication use, and intraocular pressure. Results: Patients had a diagnosis of Behcet's syndrome (two eyes), or idiopathic panuveitis (five eyes, including two with necrotizing retinitis, two with progressive chorioretinitis, and one with iridocyclitis and intermediate uveitis). Patients were observed an average of 10 months (range, 5-19 months). All eyes had stabilized or improved visual acuity after device implantation, and four of seven eyes had an improvement of three lines or more. The mean initial visual acuity, measured by Snellen chart, was 20/207, and the mean final visual acuity was 20/57 (P = 0.02). After surgery, at the final visit, no eye had clinically detectable inflammation, and all seven eyes had a marked reduction in systemic, topical, and periocular anti-inflammatory medication use. Four eyes had increased intraocular pressure 6 weeks to 6 months after device implantation. Intraocular pressure has been controlled on topical medications. No patient experienced intraoperative complications. Conclusions: A fluocinolone acetonide sustained drug delivery device is a promising new therapy for the treatment of severe uveitis. Intraocular pressure must be carefully monitored long after device implantation. Based on these data, a randomized study of a larger group of patients is warranted. Ophthalmology 2000;107: 2024-2033 (C) 2000 by the American Academy of Ophthalmology.
引用
收藏
页码:2024 / 2033
页数:10
相关论文
共 10 条
  • [1] REVIEW - IMPLANTS
    ASHTON, P
    BLANDFORD, DL
    PEARSON, PA
    JAFFE, GJ
    MARTIN, DF
    NUSSENBLATT, RB
    [J]. JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (04): : 691 - 701
  • [2] CHENG CK, 1995, INVEST OPHTH VIS SCI, V36, P442
  • [3] Methotrexate treatment for sarcoid-associated panuveitis
    Dev, S
    McCallum, RM
    Jaffe, GJ
    [J]. OPHTHALMOLOGY, 1999, 106 (01) : 111 - 118
  • [4] CATARACT-SURGERY AND INTRAOCULAR-LENS IMPLANTATION IN PATIENTS WITH UVEITIS
    FOSTER, CS
    FONG, LP
    SINGH, G
    [J]. OPHTHALMOLOGY, 1989, 96 (03) : 281 - 287
  • [5] Sustained release intravitreal dexamethasone
    Hainsworth, DP
    Pearson, PA
    Conklin, JD
    Ashton, P
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1996, 12 (01) : 57 - 63
  • [6] Dexamethasone, sustained drug delivery implant for the treatment of severe uveitis
    Jaffe, GJ
    Pearson, PA
    Ashton, P
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2000, 20 (04): : 402 - 403
  • [7] Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis
    Jaffe, GJ
    Yang, CS
    Wang, XC
    Cousins, SW
    Gallemore, RP
    Ashton, P
    [J]. OPHTHALMOLOGY, 1998, 105 (01) : 46 - 56
  • [8] Martin DF, 1999, AM J OPHTHALMOL, V127, P329
  • [9] Evaluation of a delivery system providing long-term release of cyclosporine
    Pearson, PA
    Jaffe, GJ
    Martin, DF
    Cordahi, GJ
    Grossniklaus, H
    Schmeisser, ET
    Ashton, P
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (03) : 311 - 317
  • [10] Cystoid macular edema and anterior uveitis associated with latanoprost use -: Experience and incidence in a retrospective review of 94 patients
    Warwar, RE
    Bullock, JD
    Ballal, D
    [J]. OPHTHALMOLOGY, 1998, 105 (02) : 263 - 268